Inactive Instrument

Aceragen, Inc. Nyse

ACGN

US00445F1093

Biotechnology & Medical Research

Idera Pharmaceuticals, Inc.(NasdaqCM:IDRA) added to Russell Microcap Value Index

June 25, 2021 at 12:00 am EDT

Latest news about Aceragen, Inc.

Aceragen Inc is a clinical-stage biopharmaceutical company. The Company is focused on the clinical development, and commercialization, of drug candidates for rare disease indications characterized by small, well-defined patient populations with serious unmet medical needs. The Companyâs pipeline includes ACG-701 to treat cystic fibrosis (CF) pulmonary exacerbations (PEx) and melioidosis, and ACG-801 to treat Farber disease. Its focus is to develop and optimize the commercial value of ACG-701 and ACG-801 for appropriate patients. ACG-701 is an oral, loading dose formulation of sodium fusidate being developed as a potential treatment for PEx associated with cystic fibrosis CF, a factor driving lung function decline in people living with CF. ACG-701 is also being developed for the treatment of melioidosis, a life-threatening infection that can affect numerous organ systems, including the lungs.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+22.56%	46.71B
IQVIA HOLDINGS INC.	-1.51%	41.52B
LONZA GROUP AG	+48.83%	41.8B
CELLTRION, INC.	-3.42%	29.55B
ICON PUBLIC LIMITED COMPANY	+10.13%	25.78B
ALNYLAM PHARMACEUTICALS, INC.	-20.44%	19.26B
MEDPACE HOLDINGS, INC.	+26.45%	11.98B
BIO-TECHNE CORPORATION	-0.14%	12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.47%	12.08B

Other Biotechnology & Medical Research

Aceragen, Inc. Nyse

Equities

ACGN

US00445F1093

Biotechnology & Medical Research

Idera Pharmaceuticals, Inc.(NasdaqCM:IDRA) added to Russell Microcap Value Index

Latest news about Aceragen, Inc.

Chart Aceragen, Inc.

Company Profile

Sector Other Biotechnology & Medical Research